|
Australia offers many benefits, including a favorable regulatory environment, a high quality product (drug/device) development environment, the highest disease prevalence of asthma and melanoma in the world, and seasonal reversal for respiratory, allergy and asthma studies. It’s also cost-competitive to run studies in Australia – it’s the most inexpensive in comparison with 14 other major drug development countries (Ernst and Young, Benchmarking Report, January 2001).
That’s why we have well-established operational bases in Melbourne and Sydney in Australia, and a presence in Auckland, New Zealand, which focus on clinical research, data management, regulatory affairs, development and commercialization, and health outcomes.
We have expertise across all major therapeutic areas. Our top six therapeutic areas of experience in Australia include:
- Oncology – solid tumors and hematological malignancies
- Cardiovascular – congestive heart failure, acute myocardial infarction, hypertension, DVT, cardiovascular devices
- CNS – stroke, epilepsy, Alzheimer’s disease, schizophrenia, depression
- Gastroenterology – Crohn’s disease, ulcerative colitis, GERD
- Respiratory – asthma, allergy
- Diabetes – Type I and II
|
